Clinical Trials on Erosive Esophagitis in Finland

Total 21 results

AstraZeneca

Completed

A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.

GERD With Erosive Esophagitis

Sweden, United States, France, Italy, United Kingdom, Germany, Denmark, Finland, Norway, Canada
AstraZeneca

Completed

A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.

GERD Without Erosive Esophagitis

Sweden, United States, France, Italy, United Kingdom, Germany, Denmark, Finland, Norway, Canada
AstraZeneca

Completed

NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis

Gastroesophageal Reflux Disease | Erosive Esophagitis | Reflux Esophagitis

United States
Tampere University Hospital
Carol Davila University of Medicine and Pharmacy

Active, not recruiting

Improved Diagnostics of Celiac Disease in Children

Celiac Disease | Eosinophilic Esophagitis

Finland, Romania
AstraZeneca

Completed

Sopran - Omeprazole Treatment Versus Surgery

GERD

Sweden, Norway, Denmark, Finland
Shire

Completed

OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension

Eosinophilic Esophagitis (EoE)

United States
Calypso Biotech BV

Completed

Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis

Celiac Disease | Eosinophilic Esophagitis

Netherlands, Belgium, Finland, Germany, Norway
Takeda

Completed

Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis

Esophagitis, Peptic | Esophagitis, Reflux

United States
Takeda

Completed

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

Esophagitis, Peptic | Esophagitis, Reflux

United States, Poland, Bulgaria, India, Canada, Peru, Russian Federation, Australia, New Zealand, Czech Republic, Slovakia, South Africa, Latvia, Lithuania, Colombia, Germany
AstraZeneca

Completed

Esomeprazole (NEXIUM) vs. Surgery (LOTUS)

Gastroesophageal Reflux

Italy, Sweden, Germany, Denmark, Finland, Norway, Netherlands, Austria, Belgium, United Kingdom, France, Iceland
AstraZeneca
Amgen

Recruiting

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis (CROSSING)

Eosinophilic Esophagitis

United States, Czechia, Spain, China, Australia, Italy, Belgium, Finland, Norway, Japan, Brazil, Germany, Greece, Canada, Netherlands, Sweden, Israel, Denmark, Austria, Slovakia, New Zealand, United Kingdom
Celgene

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

Eosinophilic Esophagitis

Australia, United States, Argentina, Austria, Belgium, Canada, Germany, Israel, Italy, Japan, Poland, Portugal, Spain, Switzerland, United Kingdom
Ellodi Pharmaceuticals, LP

Completed

Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2) (FLUTE-2)

Eosinophilic Esophagitis

United States, Australia, Spain
Celgene

Recruiting

Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

Eosinophilic Esophagitis

United States, Belgium, Australia, Canada, Italy, Austria, Germany, Israel, Japan, Poland, Portugal, Spain, United Kingdom, Argentina, Switzerland
Eisai Inc.

Completed

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease (GERD)

United States
Shire

Completed

Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease

United States, Czechia, Germany, Latvia, Poland, Romania
Ironwood Pharmaceuticals, Inc.

Completed

Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

Gastroesophageal Reflux Disease (GERD)

United States, Canada
Takeda

Completed

Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Gastroesophageal Reflux Disease

United States
Eisai Inc.

Completed

Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)

Symptomatic Gastroesophageal Reflux Disease (sGERD)

United States
Takeda

Completed

Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis

Esophagitis

United States
Phathom Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)

Heartburn | Non-Erosive Gastro-Esophageal Reflux Disease

United States

Clinical Trials on Erosive Esophagitis in Finland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations